Andrew Robbins

Title: Andrew Robbins: Innovator in Pharmaceutical Chemistry

Introduction

Andrew Robbins is a notable inventor based in Milton Bridge, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for therapeutic use. His work is characterized by a focus on enhancing the efficacy of treatments through novel chemical formulations.

Latest Patents

Andrew Robbins holds a patent for a compound titled "Dimethylaminoethanol salt of a GLP-1 receptor modulator - Crystalline 2-hydroxy-N,N-dimethylethanaminium 1-(2-(5-(tert-butyl)-thiophene-2-carboxamido)-3-(4-(5-(4'-ethyl-[1,1′-bi(cyclohexan)]-3-en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxylate salt." This patent encompasses methods related to the synthesis and therapeutic use of the compound, showcasing his innovative approach to drug development.

Career Highlights

Andrew Robbins is currently employed at Receptos, Inc., where he continues to push the boundaries of pharmaceutical research. His work has been instrumental in advancing the understanding of GLP-1 receptor modulators, which play a crucial role in the treatment of various metabolic disorders.

Collaborations

Throughout his career, Andrew has collaborated with esteemed colleagues such as Ephraim Vidal and Roger Bakale. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Andrew Robbins exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborative efforts continue to impact the field positively.